NEW YORK (GenomeWeb News) – Roche Applied Science said today that biotech services company AgenoLab has installed the xCelligence System, which Roche distributes through a partnership with Acea Biosciences.
Roche said Stuttgart, Germany-based AgenoLab purchased the xCelligence in April and installed it in July, making it the first customer to purchase the cell-based assay platform.
AgenoLab performs services in microbiology, molecular biology, cell culture technology, tissue engineering, and in other biomedical areas.
The system was originally developed by the San Diego-based Acea and was further developed with Roche as part of a marketing agreement the companies signed in November 2007.
Roche holds exclusive worldwide marketing rights to the technology.
The xCelligence platform is a label-free system that monitors cellular events in real time. It uses electrical impedance measurement to provide information about cell number, viability, and morphology.
Financial terms of the agreement with AgenoLab were not released.